All of Celerion's units now use VCT’s biometric verification system, which prevents dual enrollment in clinical trials.
“Biometrics is considered the most effective and safe method for identifying participants. It is very difficult to falsify,” said Phil Bach, Vice President, Global Clinical Research at Celerion, who told us the fingerprint biometric devices were added “for accuracy and speed.”
According to Bach, Celerion has been able to improve patient safety and preset data integrity in clinical research trials by using VCT.
Bach described the registry as “an invaluable tool” that has prevented participants enrolled at other Phase I centers from enrolling simultaneously in trials at Celerion units, “thus preventing a potential safety risk to the participants.”
“There has been a significant amount of participants attempting to dual enroll in Phase I and Phase II/III clinical trials that have been stopped by the Verified Clinical Trials system,” Bach added. Up to 25% of clinical research participants attempt multiple simultaneous clinical trial enrollment or other protocol violations at Phase I units, he noted.
“The incidence ranges from 2% to 12% in Phase II-IV clinical trials depending upon the therapeutic indication,” Bach said – which poses potential risks to the research participant, the site, and sponsor.
“It only takes but a few severe complications to cause a possible hold on approval of a study compound, or more importantly, a serious health issue for a participant.”